Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.20.

Several analysts have recently issued reports on the stock. Craig Hallum initiated coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a “buy” rating and a $15.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. William Blair reissued an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st.

Compass Therapeutics Trading Down 5.1%

Shares of NASDAQ CMPX opened at $5.17 on Friday. The firm’s 50-day moving average price is $5.74 and its 200-day moving average price is $5.15. The stock has a market capitalization of $931.07 million, a price-to-earnings ratio of -12.02 and a beta of 1.49. Compass Therapeutics has a 12-month low of $1.60 and a 12-month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Strs Ohio purchased a new stake in Compass Therapeutics in the 1st quarter worth about $34,000. Creative Planning purchased a new stake in Compass Therapeutics in the 2nd quarter worth about $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the 2nd quarter worth about $84,000. Invesco Ltd. raised its position in Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after purchasing an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its position in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.